In Vitro Testing Innovator CeeTox Inc Welcomes Timothy M. Mitchell As President

Timothy M. Mitchell has been named president of CeeTox Inc. in Kalamazoo, MIchigan. CeeTox's founder, James M. McKim, is now Chief Science Officer, leading an expanded research team to develop cutting edge in vitro toxicology testing technologies.
By: Lorraine Alden
 
Jan. 28, 2009 - PRLog -- KALAMAZOO, Michigan – CeeTox, the Kalamazoo-based leader for in vitro toxicology testing, has named Timothy M. Mitchell President. Mr. Mitchell previously held sales, marketing and general management roles for companies including Covance Inc, DCL Medical Laboratories, ACM Medical Laboratories, and Corning Inc.

CeeTox founder and first President, James McKim Ph.D. D.A.B.T., continues in his role as Chief Science Officer and leads CeeTox’s effort to develop and commercialize new in vitro technologies.

“I am excited to join CeeTox as we move into a new phase of growth,” said Mr. Mitchell. “We have helped many pharmaceutical and biotech companies screen new drug candidates and identify those with the lowest risk for toxicity and the highest probability of success. Our latest offerings bring robust decision making and cost-saving in vitro assays to the cosmetic, chemical, and personal care markets as well. This new line of dermal, ocular, and airway assays will help identify potential toxicity in both individual components and final formulations and will allow these companies to comply with their regulatory requirements.”

Using a robust, systems-biology approach, CeeTox originated in vitro models that help identify new drug candidates, chemicals, cosmetics, and consumer products with the lowest risk for toxicity and the highest probability of success. With screens to assess corrosion, irritation, sensitization, and to characterize toxicity in drugs and chemicals, CeeTox supports manufacturers in the pharmaceutical, chemical, and cosmetic industries and helps bring safer products to market faster.

For more information, contact Lorraine Alden, Marketing Coordinator for CeeTox, at +1-269-353-5536 or lalden@ceetox.com

# # #

Pharmaceutical, chemical, cosmetic, neutraceutical, and personal care product manufacturers are finding cost-effective alternatives to testing on animals with CeeTox's screens for dermal and ocular corrosion and irritation, acute oral toxicity, endocrine disruption, skin sensitization, photo toxicitiy, and subdermal penetration. Has it been CeeTox'd?
End
CeeTox, Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share